-
Product Insights
New![]()
Net Present Value Model: Swedish Orphan Biovitrum AB’s Pegadricase
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Swedish Orphan Biovitrum AB’s Efanesoctocog alfa
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Profile
![]()
Swedish Match AB – Company Profile
Swedish Match AB (Swedish Match) is a tobacco manufacturing company that produces and sells cigars and smokeless tobacco products. The company's product portfolio comprises snuff, snus, cigars, chewing tobacco, pipe tobacco, lighters, matches, and other related products. It sells products under Ettan, Longhorn, Nick and Johnny, The Lab, Goteborgs Rape, Catch, Kronan, Timber Wolf, America's Best Chew, Kaliber, General, White Owl, Solstickan, Redheads, Nitedals, Garcia y Vega, Thunder, Oliver Twist, and Cricket brands. Swedish Match offers disposable razors, batteries, and...
Add to Basket -
Product Insights
![]()
SWEDISH – Englewood Cancer Treatment Center – Colorado
Equip yourself with the essential tools needed to make informed and profitable decisions with our SWEDISH - Englewood Cancer Treatment Center - Colorado report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
![]()
Swedish Agency – Malmen Office Building – OEstergoetland
Equip yourself with the essential tools needed to make informed and profitable decisions with our Swedish Agency - Malmen Office Building - OEstergoetland report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
New![]()
Net Present Value Model: Eli Lilly and Co’s LY-3556050
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Acquired (Autoimmune) Hemolytic Anemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Acquired (Autoimmune) Hemolytic Anemia Drug Details: Iptacopan (LNP-023) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ABSK-021 in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ABSK-021 in Small-Cell Lung Cancer Drug Details: ABSK-021 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AlloStemspine in Low Back Pain
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AlloStemspine in Low Back Pain Drug Details: The therapeutic candidate is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Efatutazone in Myxoid Liposarcoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Efatutazone in Myxoid Liposarcoma Drug Details: Efatutazone (CS-7017) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CJ-15314 in Atopic Dermatitis (Atopic Eczema)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CJ-15314 in Atopic Dermatitis (Atopic Eczema) Drug Details: CJ-15314 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Hymecromone in Pulmonary Hypertension
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Hymecromone in Pulmonary Hypertension Drug Details:Hymecromone is under development for the treatment of pulmonary hypertension (PH)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VPO-227 in Polycystic Kidney Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VPO-227 in Polycystic Kidney Disease Drug Details: VPO-227 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pegadricase in Gouty Arthritis (Gout)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegadricase in Gouty Arthritis (Gout) Drug Details: SEL-212 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VG-201 in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. VG-201 in Pancreatic Cancer Drug Details: VG-201 is under development for the treatment of CEA...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Clesacostat Tromethamine + Ervogastat) in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.(Clesacostat Tromethamine + Ervogastat) in Non-Alcoholic Steatohepatitis (NASH)Drug Details:Clesacostat and Ervogastat is combination under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MET-4 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MET-4 in Ovarian Cancer Drug Details: MET-4 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TransCon IL-2 Beta/gamma in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TransCon IL-2 Beta/gamma in Metastatic Colorectal Cancer Drug Details: Recombinant Protein is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CLN-619 in Colon Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CLN-619 in Colon Cancer Drug Details: CLN-619 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SurVaxM in Anaplastic Astrocytoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SurVaxM in Anaplastic AstrocytomaDrug Details:SurVaxM is under development for the treatment of glioblastoma, brain cancer, recurrent...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.